|
Jun 7
|
Patents and economies of scale support Pfizer's wide moat
|
|
Jun 5
|
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?
|
|
Jun 3
|
How Moderna Went From Pandemic Hero to Vaccine Victim
|
|
Jun 2
|
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
|
|
May 23
|
GSK (LSE:GSK) Secures FDA Approval For COPD Treatment, Eyes European Nod For Blenrep
|
|
May 22
|
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
|
|
May 19
|
GSK’s Blood-Cancer Treatment Combinations Approved in Japan
|
|
Mar 12
|
The most popular stocks for investors in February
|
|
Feb 23
|
GSK plc (GSK): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
|
|
Feb 17
|
PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY
|
|
Feb 17
|
Trending tickers: TSMC, Tencent, Alibaba, GSK and BAE Systems
|
|
Feb 15
|
Here's Why We're Wary Of Buying GSK's (LON:GSK) For Its Upcoming Dividend
|
|
Feb 14
|
Hedge fund Citadel takes short position in GSK, FT reports
|
|
Feb 13
|
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis
|
|
Feb 12
|
Some May Be Optimistic About GSK's (LON:GSK) Earnings
|
|
Feb 10
|
Recent uptick might appease GSK plc (LON:GSK) institutional owners after losing 7.8% over the past year
|
|
Jan 29
|
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline
|
|
Jan 29
|
GSK announces EMA accepted for review the MAA for depemokimab
|
|
Jan 29
|
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
|
|
Jan 27
|
GSK and Oxford researchers to create cancer vaccine to stop disease developing
|